In summary, we successfully constructed a novel anti-PSMA Ab with high affinity and specificity toward the PSMA antigen and demonstrated that combined treatment with this anti-PSMA Ab and human PB-NK cells manufactured in our established NK cell expanding system enhanced the anti-tumor effect against CRPC in vitro and in vivo, which is a promising immunotherapeutic strategy for treating CRPC in clinical settings. The gene discussed is FOLH1; the disease is neoplasm.